CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Viking Therapeutics Presents Phase 3 VK2735 Obesity Trial Update

By Public Technologies
  • Viking Therapeutics expects data from two Phase 3 VANQUISH trials of injectable obesity drug VK2735 in the second half of 2027.
  • VANQUISH-1 enrolled more than 4,500 adults; VANQUISH-2 enrolled approximately 1,000 adults with type 2 diabetes.
  • Oral VK2735 is in Phase 3 SUNRISE trials, with a Phase 1 maintenance study initiated.
  • Amylin agonist VK3019 entered Phase 1 development in the second quarter of 2026.
  • Partnering discussions remain ongoing for MASH candidate VK2809 following successful completion of its Phase 2b VOYAGE trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk